Palladium Pd 103

Drug Overview

Palladium Pd 103 (also known as Palladium-103 or ¹⁰³Pd) is a radioactive isotope of the metal palladium used primarily in permanent interstitial brachytherapy. It is most commonly formulated into small, titanium-encapsulated “seeds” that are implanted directly into a tumor to deliver highly localized, low-energy radiation.

In the clinical landscape of March 2026, Palladium Pd 103 is recognized as a standard-of-care isotope for treating low-to-intermediate risk prostate cancer. Unlike external beam radiation, which travels through healthy tissue to reach the target, Palladium-103 seeds emit radiation that travels only a few millimeters. This allows for an extremely high dose to be delivered to the tumor while minimizing radiotoxicity to the adjacent rectum and bladder. Because of its specific physical properties—including a shorter half-life compared to other common isotopes like Iodine-125—it is often preferred for more aggressive or fast-growing tumors that require a higher initial dose rate to be effective.

• Generic Name: Palladium Pd 103.
• Common Name: Palladium-103.
• Drug Class: Radioactive Therapeutic Agent; Brachytherapy Source.
• Mechanism: Continuous low-dose-rate (LDR) emission of X-rays and Auger electrons to induce DNA damage and cell death.
• Route of Administration: Interstitial implantation (Seed implant).
• FDA Approval Status: FDA-approved for various permanent interstitial implants, most notably for prostate and ophthalmic (eye) cancers.

What Is It and How Does It Work? (Mechanism of Action)

Palladium Pd 103 works by providing “internal” radiation that destroys cancer cells from the inside out.

1. Low-Dose-Rate (LDR) Brachytherapy

Palladium-103 is used for permanent implants. Once the seeds are placed, they are never removed; they stay in the body and slowly lose their radioactivity over several months until they become inert.

• The Energy Profile: It emits low-energy X-rays (average energy of 21 keV). This energy is high enough to kill cancer cells but low enough to be absorbed rapidly by the surrounding tissue, preventing it from reaching distant organs.
• The Decay Process: It decays via electron capture into stable Rhodium-103.

2. The Dose Rate Advantage

The most significant difference between Palladium-103 and other isotopes is how fast it delivers its dose.

• Half-Life: It has a half-life of approximately 17 days (compared to ~60 days for Iodine-125).
• Intensity: Because it decays faster, it delivers its radiation dose more “front-loaded.” In the first few weeks, the dose rate is about three times higher than that of Iodine. This makes it theoretically more effective for cancers with a high “alpha/beta ratio,” meaning tumors that grow and divide quickly.

3. Rapid Dose Fall-off

Because of the low energy of the photons, the radiation intensity drops off sharply according to the inverse square law. This creates a “surgical” field of radiation where the tumor receives a lethal dose, but tissue just a few centimeters away receives almost no radiation at all.

Clinical Indications and Research Status (2026)

As of early 2026, Palladium Pd 103 is used in the following primary clinical settings:

• Localized Prostate Cancer: The most frequent use. It is used as monotherapy for low-risk disease or as a “boost” following external beam radiation for intermediate-to-high-risk disease.
• Uveal Melanoma (Eye Cancer): Used in “ophthalmic plaques”—gold discs containing the seeds—that are sewn onto the eye for a few days to treat tumors while sparing the optic nerve and lens.
• Unresectable Pancreatic Cancer: Research has explored the use of Pd-103 seeds during surgery to treat pancreatic tumors that cannot be fully removed, providing localized control and pain relief.
• Recent Clinical Trials (2024–2026): * Dose De-escalation: A 2026 update on randomized trials (e.g., King et al.) confirmed that lower doses of Pd-103 (110 Gy vs. the standard 125 Gy) maintain excellent cancer control with even fewer long-term urinary side effects.
  • Breast Brachytherapy: Investigated as a permanent “seed” boost for early-stage breast cancer following lumpectomy.

Technical Specifications and Characteristics

Radiation oncologists and physicists choose Palladium-103 based on these specific radioactive properties:

Comparison: Palladium-103 vs. Iodine-125

Choosing between the two most common LDR isotopes depends on the tumor’s biology and the patient’s symptoms.

• Speed: Pd-103 delivers 90% of its dose in about 58 days, while I-125 takes about 200 days.
• Symptoms: Because Pd-103 “gets the job done” faster, the acute urinary or rectal side effects may be more intense initially but often resolve much quicker (usually within 2–4 months) compared to Iodine.
• Tumor Type: Pd-103 is often favored for Gleason 7 or higher prostate cancers or cases with a higher PSA, as these faster-growing cells are more vulnerable to the higher initial dose rate.

Safety Profile and Side Effects

The side effects of Pd-103 are localized to the treatment site and generally peak within the first month.

1. Urinary Symptoms

The most common side effects for prostate patients.

• Symptoms: Frequency, urgency, and a “burning” sensation (prostatitis).
• Duration: Typically peaks at 2–4 weeks and improves significantly by 3 months.

2. Rectal Symptoms

• Symptoms: Minor irritation or increased bowel frequency (proctitis). These are generally less severe than with external radiation due to the rapid dose fall-off.

3. Radiation Precautions

Because the seeds are permanent, patients emit a very low level of radiation initially.

• Activity: Generally safe to be around others, but doctors usually recommend avoiding prolonged “lap-sitting” with children or pregnant women for the first two months.
• Travel: Patients should carry a “wallet card” provided by their facility, as the seeds can trigger sensitive radiation detectors at airports.

Patient Management and Practical Recommendations

Pre-implantation Requirements:

• Volume Study: An ultrasound-based map of the organ is created to plan the exact placement of 60–100 seeds.
• Alpha-blockers: Often started before the procedure (e.g., tamsulosin) to help with urinary flow.

“Do’s and Don’ts” List:

• DO use a strainer for your urine for the first 24–48 hours; occasionally a seed may be “passed” shortly after the procedure.
• DO carry your radiation identification card for at least 6 months after the procedure.
• DON’T worry about the seeds being “rejected”—they are made of biocompatible titanium and do not cause allergic reactions.
• DON’T sit in a hot tub or sauna for the first few weeks, as high heat can theoretically affect the surgical site healing.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Palladium Pd 103 is a radioactive material that must be handled and prescribed by a licensed radiation oncologist. Always consult with your medical physics and oncology team regarding the specific dosimetry and safety precautions associated with your radioactive implant.